Arrowhead Pharmaceuticals, Inc. (ARWR) Institutional Ownership

Ownership Summary

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) appears in 390 institutional 13F filings for the quarter ending December 2025.

• These investors collectively held 82.3% of Arrowhead Pharmaceuticals's outstanding shares in December 2025, down from 83.5% in September 2025.
• They increased total shares held in Arrowhead Pharmaceuticals by 3.94% from the prior quarter, while the number of investors in ARWR increased 45.52% year over year.
• Among the 390 funds, 247 bought more Arrowhead Pharmaceuticals shares, 109 sold down, and 34 held their ground.
• Institutional investors collectively held 115.83Mn shares in Arrowhead Pharmaceuticals as of December 2025, up by 4.39Mn shares quarter on quarter, and up 13.65Mn shares year over year.
• BlackRock, Inc. holds the largest position in ARWR at 18.16Mn shares as of December 31, 2025, or 12.91% of shares outstanding.
• Leading buyers of Arrowhead Pharmaceuticals shares for the quarter ending December 2025 were VANGUARD PORTFOLIO MANAGEMENT LLC (7.15Mn), VANGUARD CAPITAL MANAGEMENT LLC (6.03Mn), Invesco Ltd. (2.73Mn), Janus Henderson Group Plc (1.59Mn), FRED ALGER MANAGEMENT, LLC (1.51Mn).
• The biggest sellers of Arrowhead Pharmaceuticals for the quarter ending December 2025 included Avoro Capital Advisors LLC (10.55Mn), BlackRock, Inc. (3.16Mn), Goldman Sachs Group Inc (1.62Mn), ARROWSTREET CAPITAL, LIMITED PARTNERSHIP (1.5Mn), Assenagon Asset Management S.A. (626.15K).
• Business Quant data shows the 10 biggest positions in Arrowhead Pharmaceuticals as of December 2025 are held by BlackRock, Inc. (18.16Mn), Avoro Capital Advisors LLC (10.7Mn), FMR LLC (7.27Mn), VANGUARD PORTFOLIO MANAGEMENT LLC (7.15Mn), State Street Corp (6.5Mn), VANGUARD CAPITAL MANAGEMENT LLC (6.03Mn), GEODE CAPITAL MANAGEMENT, LLC (4.28Mn), FRED ALGER MANAGEMENT, LLC (3.34Mn), Invesco Ltd. (3.28Mn), Janus Henderson Group Plc (2.87Mn).